PBLA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBLA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Panbela Therapeutics's enterprise value is $5.78 Mil. Panbela Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-27.31 Mil. Therefore, Panbela Therapeutics's EV-to-EBITDA for today is -0.21.
The historical rank and industry rank for Panbela Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Panbela Therapeutics was -0.12. The lowest was -2.49. And the median was -0.27.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-25), Panbela Therapeutics's stock price is $0.36. Panbela Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-228.567. Therefore, Panbela Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Panbela Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panbela Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -6.02 | -4.98 | -1.07 | -0.25 | -0.45 |
Panbela Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.20 | -0.20 | -0.35 | -0.45 | -0.26 |
For the Biotechnology subindustry, Panbela Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Panbela Therapeutics's EV-to-EBITDA falls into.
Panbela Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 5.777 | / | -27.305 | |
= | -0.21 |
Panbela Therapeutics's current Enterprise Value is $5.78 Mil.
Panbela Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panbela Therapeutics (OTCPK:PBLA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Panbela Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.36 | / | -228.567 | |
= | At Loss |
Panbela Therapeutics's share price for today is $0.36.
Panbela Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-228.567.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Panbela Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer K. Simpson | director, officer: President and CEO | C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019 |
Susan Horvath | officer: V.P. of Finance & CFO | 4645 ITHACA LANE, PLYMOUTH MN 55446 |
Jeffrey E. Jacob | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Daniel Donovan | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Paul W. Schaffer | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Arthur Fratamico | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Ryan R. Gilbertson 2012 Irrevocable Trust | 10 percent owner | 1000 PARKER'S LAKE RD, WAYZATA MN 55391 |
Ryan Randall Gilbertson | 10 percent owner | 130 LAKE ST. WEST, WAYZATA MN 55391 |
Donald Robert Schemel | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Dalvir S Gill | director | 712 VISTA BLVD SUITE 305, WACONIA MN 55387 |
Scott Kellen | officer: Chief Financial Officer | 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447 |
Jeffrey S Mathiesen | director | 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167 |
Paulson J Robert Jr | director | |
Daniel E. Ryweck | officer: Chief Financial Officer | 712 VISTA BLVD #305, WACONIA MN 55387 |
Michael T. Cullen | director | 712 VISTA BLVD, #305, WACONIA MN 55387 |
From GuruFocus
By Marketwired • 11-03-2023
By Marketwired • 08-28-2023
By sperokesalga sperokesalga • 03-01-2023
By Marketwired • 07-24-2023
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 02-13-2023
By Stock market mentor Stock market mentor • 01-19-2023
By sperokesalga sperokesalga • 04-19-2023
By sperokesalga sperokesalga • 06-13-2023
By sperokesalga sperokesalga • 05-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.